摘要
目的:予经腮腺浅叶摘除术患者术后行山莨菪碱片(654-2)治疗,研究临床疗效。方法:选取我院收治的腮腺良性肿瘤患者50例,随机分为阿托品组(25例)、654-2组(25例),均经腮腺浅叶摘除术治疗,术后分别予以阿托品、山莨菪碱片(654-2)治疗,比较临床疗效及不良反应。结果:654-2组患者治疗有效率阿托品组相近(P>0.05);654-2组患者术后并发症发生率与阿托品组相近(P>0.05);654-2组患者不良反应发生率较阿托品组低(P<0.05)。结论:予腮腺浅叶摘除术患者术后予以山莨菪碱片(654-2)治疗,可降低药物不良反应,临床治疗安全有效。
Objective: To study the clinical effect of anisodamine tablets(654-2)on patients after parotid lobectomy. Methods: 50 patients with benign parotid tumor in our hospital were randomly divided into atropine group(25 cases)and 654-2 group(25 cases). All patients were treated with superficial parotid lobectomy, and atropine and anisodamine tablets(654-2)were given respectively after the operation. Results: The effective rate of treatment in group 654-2 was similar to that in group atropine(P>0.05);the incidence of postoperative complications in group 654-2 was similar to that in group atropine(P>0.05);the incidence of adverse reactions in group 654-2 was lower than that in group atropine(P<0.05). Conclusion: Anisodamine tablets(654-2) can reduce the adverse drug reactions in patients with parotid lobectomy, and the clinical treatment is safe and effective.
作者
彭定春
PENG Ding-chun(Nanfeng People’s Hospital,Fuzhou Jiangxi 344500,China)
出处
《药品评价》
CAS
2019年第18期59-60,共2页
Drug Evaluation
